Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) target price raised to $8.00, reported today by B. Riley
- Updated: September 15, 2016
Stating a possible upside of 1.14%, B. Riley bumped the estimated target of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) to $8.
Showing a price of $3.74, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) traded 1.58% lower on the day. With the last stock price down 33.11% from the 200-day average, compared to the S&P 500 which has decreased -0.01% over the same period. EKSO has logged a 50-day average of $4.47 and two hundred day average of $5.59. 64,893 shares of Ekso Bionics Holdings, Inc. exchanged hands, down from ann avg. trading volume of 188,838
See Chart Below:
With a market capitalization of $0.0, Ekso Bionics Holdings, Inc. has a one-year low of $3.64 and a one-year high of $10.08 with a price-earnings ratio of 0.
General Company Details For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Asia. The company operates through Engineering Services and Medical segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, stroke, and other lower limb paralysis or weakness. The companyÂ’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a collaborative partnership with Lockheed Martin Corporation to develop products for military applications, as well as a license agreement with OttoBock Healthcare Products Gmbh. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital, and PA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.